Dicot Pharma AB

3 countries, 6 clinics, 140 patients. We have just got the authorization to start our phase 2a study! Now, we set out to confirm the efficacy signal detected in the phase 1-study together with Clinical Trial Consultants, who were also the responsible CRO in phase 1.   Read all about the study and the chosen countries here: https://lnkd.in/dP8MnQEc #CTC #clinicaltrialconsultants #pharma #pharmaceutical #drugdevelopent #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

Arizona this weekend. Our CSO Charlotta Gauffin and Dr Harin Padma-Nathan, representing Dicot Pharma at the biggest sexual medicine conference in the US, attracted a lot of attention when presenting the in-depth results from our phase 1 study. In Dr Padma-Nathan´s words: "It’s been a quarter-century of wait for a new class of oral medications for erectile dysfunction. The assembled experts at SMSNA, particularly those involved in the original Viagra research, clearly understood that a strong signal had emerged from the phase 01 study, that the wait is finally over and that the entire treatment regimen for erectile dysfunction may soon be revolutionized”. Read more here: https://lnkd.in/dyWSWJQh #SMSNA #pharma #pharmaceutical #drugdevelopent #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

We are heading towards Nasdaq First North! The timing is ideal, and we are confident that this move will support our continued growth, internationalization, and competitiveness. The listing is planned to take place in November, with the exact date to be announced when confirmed. We have now taken a significant step by engaging well-renowned #FNCA as our Certified Advisor. No action is required from shareholders or warrant holders, as trading will automatically transfer to First North upon Nasdaq's approval. Read all about it below. #NFN #Nasdaqfirstnorthgrowthmarket #FNCA #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

Team Dicot Pharma is in execution mode. Following the successful rights issue, we are pleased to present an operational update. Key highlights include: -Phase 2a study set to begin shortly -Advancement of R&D activities -Planned listing on Nasdaq First North -Initiation of preclinical studies for new indications in metabolic diseases "We are in a favorable position, both financially and in terms of study results. Developing the next generation of potency drugs remains our core business, and thanks to the outcome of the rights issue, we now have the capacity to expand and explore new indications. We are very excited about what lies ahead", comments Elin. Read the full update, including further important news, here: https://lnkd.in/dhTTcHrr #operationalupdate #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

Vill du jobba med utvecklingen av nästa generation potensläkemedel och bidra till att miljoner män och par får ett bättre samliv? Nu söker vi en Senior CMC Project Manager som ska förstärka vårt redan starka team. Med placering i Uppsala kommer du ansvara för att samordna vår CMC-verksamhet inklusive utveckling och implementering av strategier. Du är även den primära CMC-kontakten mot tillverkare och leverantörer. Välkommen till en dynamisk organisation med höga ambitioner där du kommer samarbeta med erfarna och kompetenta kollegor i en kreativ, internationell och innovativ miljö. Och är det här inte du, hjälp oss jättegärna sprida ordet. Läs mer om tjänsten här: https://lnkd.in/dkub3xZZ #nyttjobb #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

The outcome of our rights issue is here: it was subscribed to 124%! Through this we will receive proceeds of appr. SEK 135 million before issuing costs. Fantastic news! Or as our hardworking CEO Elin puts it: -We are extremely pleased with the strong support from our current shareholders, and from new investors. The rights issue being oversubscribed indicates on the big interest in Dicot Pharma and the credence to our drug development. With this fine outcome, we can take LIB-01 through the so-called proof of concept phase, while also investing in the development of new indications. We want to express our warm gratitude to all of you who have supported us and will make sure to handle your trust with care. Read more about the outcome here: https://lnkd.in/drVvMJGk #rightsissue2024 #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

We're approaching the final day for subscription in our rights issue. Friday, August 30, is the official last day, but please note that some banks and nominees have an earlier date for subscription deadlines.   For those interested in trading unit rights, the last day to do so is tomorrow, August 27.   For more details in Swedish, visit: https://lnkd.in/drhRvzcH. And in English: https://lnkd.in/d6ibqxRB #rightsissue2024 #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

Edition 299 of Penserpodden, one of Sweden's leading financial podcasts, features a special guest appearance by our articulate CEO, Elin. In this episode, she shares the fascinating history of Dicot Pharma and, of course, our vision for the future.   Tune in here: https://lnkd.in/diPwTiXE #penserpodden #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

This week, our Dicot Pharma Team took to the studio for a live-streamed presentation and follow-up interview. Many tuned in and sent questions, which moderator Kaarlo Airaxin brought to the team. Questions such as: Who and what decides if LIB-01 becomes a first-line treatment? And will the management team subscribe to the current rights issue? Hear the answers and watch the full presentation here (in Swedish): https://lnkd.in/dP7JHYPx. #infront #stockpicker #investortarget #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions  #erectiledysfunction #prematureejaculation #lifescience  #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner  #erektionssvikt #tidigutlösning

A fresh edition of DICOTnytt is now available! Stay informed with the latest updates, presented in a concise and reader-friendly format. Dive into the news here (in Swedish): https://lnkd.in/d9qa94-P #DICOTnytt #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning